» Articles » PMID: 35819006

Comparative Health Systems Analysis of Differences in the Catastrophic Health Expenditure Associated with Non-communicable Vs Communicable Diseases Among Adults in Six Countries

Overview
Date 2022 Jul 12
PMID 35819006
Authors
Affiliations
Soon will be listed here.
Abstract

The growing burden of non-communicable diseases (NCDs) in low- and middle-income countries may have implications for health system performance in the area of financial risk protection, as measured by catastrophic health expenditure (CHE). We compare NCD CHE to the CHE cases caused by communicable diseases (CDs) across health systems to examine whether: (1) disease burden and CHE are linked, (2) NCD CHE disproportionately affects wealthier households and (3) whether the drivers of NCD CHE differ from the drivers of CD CHE. We used the Study on Global Aging and Adult Health survey, which captured nationally representative samples of 44 089 adults in China, Ghana, India, Mexico, Russia and South Africa. Using two-part regression and random forests, we estimated out-of-pocket spending and CHE by disease area. We compare the NCD share of CHE to the NCD share of disability-adjusted life years (DALYs) or years of life lost to disability and death. We tested for differences between NCDs and CDs in the out-of-pocket costs per visit and the number of visits occurring before spending crosses the CHE threshold. NCD CHE increased with the NCD share of DALYs except in South Africa, where NCDs caused more than 50% of CHE cases but only 30% of DALYs. A larger share of households incurred CHE due to NCDs in the lowest than the highest wealth quintile. NCD CHE cases were more likely to be caused by five or more health care visits relative to communicable disease CHE cases in Ghana (P = 0.003), India (P = 0.004) and China (P = 0.093). Health system attributes play a key mediating factor in how disease burden translates into CHE by disease. Health systems must target the specific characteristics of CHE by disease area to bolster financial risk protection as the epidemiological transition proceeds.

Citing Articles

Projecting temperature-related dengue burden in the Philippines under various socioeconomic pathway scenarios.

Seposo X, Valenzuela S, Apostol G, Wangkay K, Lao P, Enriquez A Front Public Health. 2025; 12:1420457.

PMID: 39764196 PMC: 11701004. DOI: 10.3389/fpubh.2024.1420457.


The financial burden of noncommunicable diseases from out-of-pocket expenditure in sub-Saharan Africa: a scoping review.

Odunyemi A, Islam M, Alam K Health Promot Int. 2024; 39(5).

PMID: 39284918 PMC: 11405128. DOI: 10.1093/heapro/daae114.


The 30 Years of Shifting in The Indonesian Cardiovascular Burden-Analysis of The Global Burden of Disease Study.

Muharram F, Multazam C, Mustofa A, Socha W, Andrianto , Martini S J Epidemiol Glob Health. 2024; 14(1):193-212.

PMID: 38324147 PMC: 11043320. DOI: 10.1007/s44197-024-00187-8.


Hypertension care cascades and reducing inequities in cardiovascular disease in low- and middle-income countries.

Stein D, Reitsma M, Geldsetzer P, Agoudavi K, Aryal K, Bahendeka S Nat Med. 2024; 30(2):414-423.

PMID: 38278990 DOI: 10.1038/s41591-023-02769-8.


An Ayurvedic Medication (Chyawanprash) as a Prophylaxis for Non-Communicable Disease and Communicable Disease: A Protocol for Systematic Review and Meta-Analysis.

Sharma S, Kumari K, Sethuraman G, Abdelwahab M, Sivaperumal Yadav S, Nandini V Cureus. 2023; 15(10):e47555.

PMID: 38021581 PMC: 10665970. DOI: 10.7759/cureus.47555.


References
1.
Ansah E, Powell-Jackson T . Can we trust measures of healthcare utilization from household surveys?. BMC Public Health. 2013; 13:853. PMC: 3848569. DOI: 10.1186/1471-2458-13-853. View

2.
Flores G, ODonnell O . Catastrophic medical expenditure risk. J Health Econ. 2016; 46:1-15. DOI: 10.1016/j.jhealeco.2016.01.004. View

3.
Engelgau M, Karan A, Mahal A . The Economic impact of Non-communicable Diseases on households in India. Global Health. 2012; 8:9. PMC: 3383461. DOI: 10.1186/1744-8603-8-9. View

4.
Sangar S, Dutt V, Thakur R . Comparative Assessment of Economic Burden of Disease in Relation to Out of Pocket Expenditure. Front Public Health. 2019; 7:9. PMC: 6362399. DOI: 10.3389/fpubh.2019.00009. View

5.
Khatib R, Mckee M, Shannon H, Chow C, Rangarajan S, Teo K . Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet. 2015; 387(10013):61-9. DOI: 10.1016/S0140-6736(15)00469-9. View